Literature DB >> 2863979

Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.

J B Halter, W K Ward, D Porte, J D Best, M A Pfeifer.   

Abstract

The degree of fasting hyperglycemia in patients with non-insulin-dependent diabetes mellitus is dependent on the rate of hepatic glucose production. The basal rate of hepatic glucose production is increased in patients with non-insulin-dependent diabetes mellitus, and there is a positive correlation between hepatic glucose production and fasting glucose levels. Diminished secretion of insulin, impaired hepatic sensitivity to insulin's effects, or a combination of these factors could contribute to the elevated hepatic glucose production in patients with non-insulin-dependent diabetes mellitus. The relationship between insulin secretion and hepatic glucose production is regulated by a closed feedback loop operating between glucose levels and pancreatic beta cells. Although fasting insulin levels are usually comparable between patients with non-insulin-dependent diabetes mellitus and normal subjects, insulin secretion is markedly impaired in non-insulin-dependent diabetes mellitus in relation to the degree of hyperglycemia present. In fact, the degree of fasting hyperglycemia in a given patient with non-insulin-dependent diabetes mellitus is closely related to the degree of impaired pancreatic beta-cell responsiveness to glucose. Such findings suggest that impaired insulin secretion leads to increased hepatic glucose production, which raises the plasma glucose level. The resulting hyperglycemia helps to maintain relatively normal basal insulin output. Chronic sulfonylurea drug therapy of patients with non-insulin-dependent diabetes mellitus enhances pancreatic islet sensitivity to glucose, leading to increased insulin secretion, suppression of hepatic glucose production, and a decline in the steady-state fasting glucose level.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863979     DOI: 10.1016/0002-9343(85)90579-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice.

Authors:  Hana Alkhalidy; Will Moore; Aihua Wang; Jing Luo; Ryan P McMillan; Yao Wang; Wei Zhen; Matthew W Hulver; Dongmin Liu
Journal:  J Nutr Biochem       Date:  2018-05-01       Impact factor: 6.048

2.  Population pharmacodynamic modeling of hyperglycemic clamp and meal tolerance tests in patients with type 2 diabetes mellitus.

Authors:  Ying Hong; Jasper Dingemanse; Patricia Sidharta; Donald E Mager
Journal:  AAPS J       Date:  2013-08-01       Impact factor: 4.009

3.  Insulin secretion and insulin sensitivity defects are a common feature of mild, clinically homogeneous, recently diagnosed type II (non-insulin-dependent) diabetics.

Authors:  E Pisu; A Lombardi; D De Benedictis; C Bozzo; E Chiara; C Baggiore; A Bruno; L Cravero; G Pagano; G Lenti
Journal:  Acta Diabetol Lat       Date:  1986 Jul-Sep

4.  Abnormal glucose metabolism in heterozygous mutant mice for a type I receptor required for BMP signaling.

Authors:  Gregory J Scott; Manas K Ray; Toni Ward; Kelly McCann; Shyamal Peddada; Fang-Xu Jiang; Yuji Mishina
Journal:  Genesis       Date:  2009-06       Impact factor: 2.487

5.  Driver versus navigator causation in biology: the case of insulin and fasting glucose.

Authors:  Manawa Diwekar-Joshi; Milind Watve
Journal:  PeerJ       Date:  2020-12-11       Impact factor: 2.984

6.  Inferring causal pathways among three or more variables from steady-state correlations in a homeostatic system.

Authors:  Suraj Chawla; Anagha Pund; Vibishan B; Shubhankar Kulkarni; Manawa Diwekar-Joshi; Milind Watve
Journal:  PLoS One       Date:  2018-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.